Home
>
National Drug Code (NDC)
>
LIPODOX
LIPODOX - 47335-082-50 - (Doxorubicin Hydrochloride)
Drug Information of LIPODOX
| Product NDC: | 47335-082 |
| Proprietary Name: | LIPODOX |
| Non Proprietary Name: | Doxorubicin Hydrochloride |
| Active Ingredient(s): | 2 mg/mL & nbsp; Doxorubicin Hydrochloride |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTABLE, LIPOSOMAL |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LIPODOX
| Product NDC: | 47335-082 |
| Labeler Name: | Sun Pharma Global FZE |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | |
| Marketing Category: | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Start Marketing Date: | 20120209 |
Package Information of LIPODOX
| Package NDC: | 47335-082-50 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 PACKAGE (47335-082-50) > 10 mL in 1 VIAL, SINGLE-USE |
NDC Information of LIPODOX
| NDC Code | 47335-082-50 |
| Proprietary Name | LIPODOX |
| Package Description | 1 VIAL, SINGLE-USE in 1 PACKAGE (47335-082-50) > 10 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 47335-082 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Doxorubicin Hydrochloride |
| Dosage Form Name | INJECTABLE, LIPOSOMAL |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20120209 |
| Marketing Category Name | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Labeler Name | Sun Pharma Global FZE |
| Substance Name | DOXORUBICIN HYDROCHLORIDE |
| Strength Number | 2 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Anthracycline Topoisomerase Inhibitor [EPC],Anthracyclines [Chemical/Ingredient],Topoisomerase Inhibitors [MoA] |
